[{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Baring Private Equity Asia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Fruquintinib","moa":"c-MET","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Baring Private Equity Asia","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Baring Private Equity Asia"},{"orgOrder":0,"company":"Hutchmed","sponsor":"GL Mountrose Investment Two","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Savolitinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Hutchmed \/ GL Mountrose Investment Two","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ GL Mountrose Investment Two"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"c-Met","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Fruquintinib","moa":"VEGFR 1","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"c-Met","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ HUTCHMED","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ HUTCHMED"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Savolitinib","moa":"MET","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"MET","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"TYK","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"MET tyrosine kinase","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"HMPL-523","moa":"SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"National Healthcare Security Administration","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Fruquintinib","moa":"VEGFR","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ National Healthcare Security Administration","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ National Healthcare Security Administration"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"HMPL-523","moa":"SYK","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR 1","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"HMPL-453","moa":"FGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Savolitinib","moa":"c-MET receptor tyrosine kinase","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR 1","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMG-007","moa":"OX40","graph1":"Dermatology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Neurology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Epizyme","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Epizyme"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMG-007","moa":"OX40","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"7","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Savolitinib","moa":"MET","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"HMPL-A83","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"Methyltransferase","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGF 1\/2\/3","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Eli Lilly"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Neurology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ HUTCHMED","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ HUTCHMED"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ AstraZeneca"},{"orgOrder":0,"company":"Hutchmed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"EGFR","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGF 1\/2\/3","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sovleplenib","moa":"Syk","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sovleplenib","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"National Healthcare Security Administration","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Savolitinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ National Healthcare Security Administration","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ National Healthcare Security Administration"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":1.1299999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":1.1299999999999999,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Takeda"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Amdizalisib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":1.1299999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":1.1299999999999999,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"HMPL-453","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Eli Lilly"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"IMG-004","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Hutchmed","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Hutchmed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"HMPL-415S1","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sovleplenib","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Savolitinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sovleplenib","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"HONG KONG","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"IMG-007","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Hutchmed","amount2":0.46000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.46000000000000002,"dosageForm":"Infusion","sponsorNew":"Hutchmed \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sovleplenib","moa":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Savolitinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hutchmed \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Innovent Biologics"},{"orgOrder":0,"company":"Hutchmed","sponsor":"HengRui","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Hengrui","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Hengrui"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"HMPL-306","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"HMPL-506","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"HengRui","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Surufatinib","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hutchmed \/ Hengrui","highestDevelopmentStatusID":"9","companyTruncated":"Hutchmed \/ Hengrui"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Not Applicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Fruquintinib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Hutchmed","amount2":1.1299999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Hutchmed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Hutchmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchmed \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Hutchmed

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Fruzaqla (fruquintinib) is the first and only selective inhibitor of all three VEGF receptor kinases approved for previously treated mCRC regardless of biomarker status.

                          Brand Name : Fruzaqla

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 21, 2024

                          Lead Product(s) : Fruquintinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Takeda has the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside of mainland China, Hong Kong and Macau, and markets under the Fruzaqla brand name.

                          Brand Name : Fruzaqla

                          Molecule Type : Small molecule

                          Upfront Cash : $400.0 million

                          October 31, 2024

                          Lead Product(s) : Fruquintinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Takeda Pharmaceutical

                          Deal Size : $1,130.0 million

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Tagrisso (osimertinib) is being evaluated in the mid-stage clinical trial studies in combination with Orpathys (savolitinib) for EFGR-mutated non-small cell lung cancer.

                          Brand Name : Tagrisso

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 16, 2024

                          Lead Product(s) : Osimertinib Mesylate,Savolitinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : HMPL-013 (fruquintinib) is the first and only selective inhibitor of all three VEGF receptor kinases which is being evaluated for the treatment of gastroesophageal junction adenocarcinoma.

                          Brand Name : HMPL-013

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 29, 2024

                          Lead Product(s) : Fruquintinib,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Tazverik (tazemetostat) is a first-in-class methyltransferase inhibitor of EZH2, which is being evaluated for the treatment of relapsed or refractory follicular lymphoma.

                          Brand Name : Tazverik

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 03, 2024

                          Lead Product(s) : Tazemetostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : HMPL-506 is a novel, investigational, selective small molecule inhibitor for oral administration targeting the menin protein. It is being investigated for MLL-rearranged relapsed/refractory AML.

                          Brand Name : HMPL-506

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 06, 2024

                          Lead Product(s) : HMPL-506

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Hutchmed will initiate a clinical advancement of their lead product Sulanda (surufatinib) in combination with camrelizumab for the treatment of naïve pancreatic ductal adenocarcinoma.

                          Brand Name : Sulanda

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 15, 2024

                          Lead Product(s) : Surufatinib,Camrelizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : HengRui

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Fruzaqla (fruquintinib) is a selective oral VEGFR inhibitor, playing a pivotal role in blocking tumor angiogenesis. It is being investigated in combination with sintilimab for endometrial cancer.

                          Brand Name : Fruzaqla

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 13, 2024

                          Lead Product(s) : Fruquintinib,Sintilimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : HengRui

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : HMPL-306 is a novel selective small molecule dual inhibitor of isocitrate dehydrogenase 1 and 2 mutations. It is being evaluated in the phase III for relapsed/refractory acute myeloid leukemia.

                          Brand Name : HMPL-306

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 13, 2024

                          Lead Product(s) : HMPL-306

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Fruzaqla (fruquintinib) is a selective oral VEGFR inhibitor blocking tumor angiogenesis. It is being investigated with sintilimab (PD-1 inhibitor) for treating advanced endometrial cancer.

                          Brand Name : Fruzaqla

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 01, 2024

                          Lead Product(s) : Fruquintinib,Sintilimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Innovent Biologics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank